T-1- and T-2*-dominant extravasation correction in DSC-MRI: Part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients

Kyrre E. Emblem*, Atle Bjornerud, Kim Mouridsen, Ronald J. H. Borra, Tracy T. Batchelor, Rakesh K. Jain, A. Gregory Sorensen

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    33 Citations (Scopus)

    Abstract

    A 'vascular normalization index' (VNI) based on the changes in the magnetic resonance imaging (MRI) parameters K-trans and cerebral blood volume (CBV), combined with blood sampling, has been shown to correlate with patient outcome in recurrent glioblastoma after a single dose of antiangiogenic therapy. Here, by applying a novel contrast agent extravasation correction method insensitive to variations in tissue mean transit time, we show that a similar VNI parameter can be derived from a single dynamic susceptibility contrast MR acquisition rather than the three parameters shown previously. Our results show that this new VNI parameter, which combines changes in tumoral CBV and an apparent transfer constant from our leakage correction method, may provide prognostic information in an even simpler manner than prior efforts. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 2054-2064; doi:10.1038/jcbfm.2011.39; published online 20 April 2011

    Original languageEnglish
    Pages (from-to)2054-2064
    Number of pages11
    JournalJournal of Cerebral Blood Flow and Metabolism
    Volume31
    Issue number10
    DOIs
    Publication statusPublished - Oct-2011

    Keywords

    • anti-VEGF
    • DSC-MRI
    • glioblastoma
    • leakage correction
    • survival analysis
    • CEREBRAL BLOOD-VOLUME
    • SUSCEPTIBILITY CONTRAST MRI
    • BRAIN-BARRIER PERMEABILITY
    • ENHANCED T-1-WEIGHTED MRI
    • HIGH-GRADE
    • MICROVASCULAR PERMEABILITY
    • AGENT EXTRAVASATION
    • GLIOMA GRADE
    • PERFUSION
    • TUMORS

    Fingerprint

    Dive into the research topics of 'T-1- and T-2*-dominant extravasation correction in DSC-MRI: Part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients'. Together they form a unique fingerprint.

    Cite this